Welcome to our dedicated page for Zymeworks SEC filings (Ticker: ZYME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zymeworks’ latest SEC filings read like a dense lab notebook—hundreds of pages on antibody engineering, milestone payments, and cash runway projections. If you have ever asked “How do I find Zymeworks insider trading Form 4 transactions?” or “Where is the Zymeworks quarterly earnings report 10-Q filing?” you know the challenge.
Stock Titan turns that challenge into a quick scan. Our AI parses every Zymeworks annual report 10-K, flags pivotal trial results, and delivers plain-English explanations of licensing revenue swings. Need real-time alerts? You’ll see Zymeworks Form 4 insider transactions in seconds—no EDGAR scroll required. The platform also highlights 8-K material events explained, summarizes pipeline disclosures inside each 10-Q, and links directly to the proxy statement executive compensation section.
- Track Zymeworks executive stock transactions Form 4 before key data releases
- Compare R&D spend quarter-over-quarter with our Zymeworks earnings report filing analysis
- Spot cash-runway warnings and partnership milestones—Zymeworks SEC filings explained simply
Whether you’re monitoring “understanding Zymeworks SEC documents with AI” or need a Zymeworks annual report 10-K simplified, our comprehensive feed updates the moment a document hits EDGAR. Complex biotech language becomes actionable insight—so you can focus on decisions, not downloads.
EcoR1 Capital, LLC and affiliates have filed a Schedule 13D disclosing a 30.7% beneficial stake in Zymeworks Inc. (NASDAQ: ZYME). The group, which includes EcoR1 Capital Fund Qualified, L.P. and EcoR1 founder Oleg Nodelman, now controls 22,970,388 common shares following the recent exercise of pre-funded warrants. The ownership percentage is based on 74,844,505 shares outstanding as reported in Zymeworks’ Form 8-K dated 27 Jun 2025.
Capital deployed. EcoR1 funds have invested a cumulative $205.7 million in ZYME equity: $192.9 million by the Qualified Fund and $12.9 million by EcoR1 Capital Fund, L.P. The totals include $50.0 million used on 26 Dec 2023 to acquire pre-funded warrants that have since been exercised.
Governance influence. Oleg Nodelman and EcoR1 employee Scott Platshon already sit on Zymeworks’ board, giving the investor direct insight and influence over corporate strategy. The filing states that the shares were acquired for investment purposes and that no specific plans under Items 4(a)-(j) of Schedule 13D are currently contemplated; however, EcoR1 reserves the right to buy or sell additional shares, engage in hedging, or discuss strategic matters with management and other shareholders.
Key takeaways for investors:
- EcoR1 is now Zymeworks’ largest known holder, with voting and dispositive power shared among its entities.
- The stake underscores EcoR1’s conviction that ZYME was undervalued at the time of purchase.
- While the filing is not overtly activist, EcoR1’s 30%-plus position and board presence could accelerate strategic initiatives or heighten takeover speculation.
- Potential share-price volatility may arise if EcoR1 materially increases or reduces its position.
Zymeworks (Nasdaq: ZYME) filed an 8-K announcing two material events.
- Amendment: The company removed the 19.99 % ownership cap from 5,086,521 pre-funded warrants originally sold to EcoR1 in December 2023.
- Exercise: On June 26 2025 the warrants were net-exercised at $0.0001; 5,086,480 common shares were issued on June 27 2025.
The exercise lifted the warrant overhang but adds ≈6.8 % to the basic share count, which now totals 74,844,505. Because the warrants were already deeply in-the-money, cash proceeds were immaterial (≈$509) and no additional capital was raised. EcoR1—already a >5 % holder with board representation—can now exceed the prior 19.99 % limit, increasing ownership concentration and voting power.
No financial statements or guidance were provided.
FAQ
What is the current stock price of Zymeworks (ZYME)?
What is the market cap of Zymeworks (ZYME)?
What is the core focus of Zymeworks?
What proprietary technologies does Zymeworks utilize?
How does Zymeworks differentiate itself in the competitive biotech landscape?
What therapeutic areas are targeted by Zymeworks' products?
How does the Company advance its product candidates into clinical development?
What is the significance of the Azymetric™ platform?
How do strategic partnerships factor into Zymeworks' business model?
